Literature DB >> 12064808

Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease.

Maeve O'Connor1, Alan Buchman, Gailen Marshall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12064808     DOI： 10.1023/a:1015326715456

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  11 in total

Review 1.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors:  W J Sandborn; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

2.  Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction.

Authors:  T C Puchner; S Kugathasan; K J Kelly; D G Binion
Journal:  Inflamm Bowel Dis       Date:  2001-02       Impact factor: 5.325

3.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 4.  Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications.

Authors:  F J Baert; P R Rutgeerts
Journal:  Int J Colorectal Dis       Date:  1999-02       Impact factor: 2.571

Review 5.  Rituximab.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 6.  Antibodies in the therapy of colon cancer.

Authors:  S Welt; G Ritter
Journal:  Semin Oncol       Date:  1999-12       Impact factor: 4.929

Review 7.  Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.

Authors:  A F Kavanaugh
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

Review 8.  Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective.

Authors:  W J Wallis; D E Furst; V Strand; E Keystone
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

Review 9.  Edrecolomab (monoclonal antibody 17-1A).

Authors:  J C Adkins; C M Spencer
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 10.  Monoclonal antibody-based therapies for hematologic malignancies.

Authors:  P S Multani; M L Grossbard
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544
View more
  2 in total

Review 1.  Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.

Authors:  Peter D Han; Russell D Cohen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs.

Authors:  Ditina Desai; Raphaela Goldbach-Mansky; Joshua D Milner; Ronald L Rabin; Keith Hull; Frank Pucino; Nona Colburn
Journal:  Ann Pharmacother       Date:  2009-05       Impact factor: 3.154
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.